The organ-on-chip market is anticipated to grow at a CAGR of 21.3% till 2035, claims Roots Analysis
18 oct. 2022 08h00 HE
|
Roots Analysis
London, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Organ on a Chip Market, 2022-2035: Focus on Products and Technologies” report to its list of offerings. With...
The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis
27 juil. 2022 10h00 HE
|
Roots Analysis
London, July 27, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Gene Therapy Market” report to its list of offerings. Post the emergence of blockbuster gene therapies, such...
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
03 juin 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
12 mai 2022 07h30 HE
|
Decibel Therapeutics, Inc.
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and...
Decibel Therapeutics to Participate in Upcoming Investor Conferences
22 mars 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
06 déc. 2021 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
22 nov. 2021 07h30 HE
|
Decibel Therapeutics, Inc.
Collaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development...
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
08 nov. 2021 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
30 sept. 2021 17h42 HE
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
The Fc protein and glyco-engineered antibodies market is projected to grow at a CAGR of over 30% during 2021-2030, claims Roots Analysis
14 sept. 2021 08h15 HE
|
Roots Analysis
London, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings. Over time, a...